- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01344070
Generic Formulations of Commonly-used Oral Drugs in Saudi Arabia:Interchangeability & Post-marketing Quality
Generic Formulations of Commonly-Used, Immediate-Release, Solid, Oral, Drugs in Saudi Arabia: Interchangeability & Post-Marketing Quality
Generic formulations of prescription drugs can, through their relatively lower cost, improve healthcare as long as they maintain their registration-quality and public trust. On the other hand, the market availability of several generic formulations raises a concern regarding their interchangeability, despite being proven to be individually therapeutically interchangeable with their corresponding innovator formulation.
The investigators propose to assess the quality and therapeutic interchangeability of generic formulations in the drug market of Saudi Arabia, using fifteen, commonly-used, oral, solid, immediate-release, and non-combinational drugs.
Study Overview
Status
Detailed Description
Generic formulations of prescription drugs can, through their relatively lower cost, improve healthcare as long as they maintain their registration-quality and public trust. On the other hand, the market availability of several generic formulations raises a concern regarding their interchangeability, despite being proven to be individually therapeutically interchangeable with their corresponding innovator formulation.
The investigators propose to assess the quality and therapeutic interchangeability of generic formulations in the drug market of Saudi Arabia, using fifteen, commonly-used, oral, solid, immediate-release, and non-combinational drugs.
The following drugs have been identified from the Saudi National Formulary (September 2006) as having, among oral, immediate-release, non-combinational drugs, the highest number of formulations (they have each 15 to 47): ciprofloxacin, ranitidine, amoxicillin, paracetamol, atenolol, cephalexin, ibuprofen, diclofenac, metformin, omeprazole, metronidazole, enalapril, clarithromycin, amlodipine, and fluconazole. In the first set of studies and for each drug, a four-treatment, four-period, four-sequence, crossover bioequivalence study will be conducted on the innovator and three randomly-selected generic formulations. Each study will be designed to have a power of 0.9 to detect bioequivalence, and sampling and wash-out periods of at least 5 and 7 half lives, respectively. Individuals who are identified in the first set of studies as having the large intra-subject variation (bioequivalence parameters ratios of less the 80% or more than 120% for AUC) will be subjected to a second set of studies, in which 2 batches of the reference formulation (including the batch used in the first set of studies) and the generic formulation will be compared in a two-treatment, four-period, two-sequence, replicate design crossover bioequivalence study. Drug levels will be determined by an HPLC or LC-MS-MS method, locally-validated according to international guidelines. After log transformation, AUC and Cmax (non-compartmental model) of the formulations will be compared pair-wise by ANOVA. Pair-wise bioequivalence will be tested by 90% (and 95%) confidence interval of ratios and Schuirmann's two one sided t-tests for the 70-143, 80-125%, and 90-112% ranges. The following will be determined: 1) the prevalence of generic formulations that are not bioequivalent to their innovator formulation, 2) the prevalence of the phenomena that two generics of the same innovator formulation are not bioequivalent to each other, 3) the percentage of individuals with large intra-subject variation despite the presence of average bioequivalence between the two formulations, and 4) how much of the large intra-subject variation in 3 above is true or related, in part, to product failure, random error, or subject-by-formulation interaction; and how it compares to intra-subject variability when two batches of the innovator formulation are compared.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Riyadh, Saudi Arabia, 11211
- King Faisal Specialist Hospital & Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- No evidence of clinically important deviation from normal health as indicated by a recent physical examination, medical history, and clinical laboratory tests (complete blood count, renal and hepatic profiles, and routine urinalysis.
- Body Mass Index (BMI) should be less than 35 kg/m2.
- Acceptance to abstain from taking any medication (including over-the-counter [OTC] drugs) for at least 2 weeks prior to, and during the study; and from smoking and taking alcohol or caffeine or related xanthenes-containing beverages or food for 48 hours before taking the study drug and throughout each of the two blood sampling periods.
Exclusion Criteria:
- any contraindication to use the drug.
- any history of hypersensitivity to the drug to be tested or related compounds.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Reference formulation of each drug
Innovator formulation
|
single, oral, immediate-release, non-combinational innovator formulation
single, oral, immediate-release, non-combinational generic formulation a
single, oral, immediate-release, non-combinational generic formulation b
single, oral, immediate-release, non-combinational generic formulation c
|
Active Comparator: generic formulation a
one of the several generic formulations in the market, randomly selected for each drug
|
single, oral, immediate-release, non-combinational innovator formulation
single, oral, immediate-release, non-combinational generic formulation a
single, oral, immediate-release, non-combinational generic formulation b
single, oral, immediate-release, non-combinational generic formulation c
|
Active Comparator: generic formulation b
second of the several generic formulations in the market, randomly selected for each drug
|
single, oral, immediate-release, non-combinational innovator formulation
single, oral, immediate-release, non-combinational generic formulation a
single, oral, immediate-release, non-combinational generic formulation b
single, oral, immediate-release, non-combinational generic formulation c
|
Active Comparator: generic formulation c
third of the several generic formulations in the market, randomly selected for each drug
|
single, oral, immediate-release, non-combinational innovator formulation
single, oral, immediate-release, non-combinational generic formulation a
single, oral, immediate-release, non-combinational generic formulation b
single, oral, immediate-release, non-combinational generic formulation c
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
bioequivalence
Time Frame: ciprofloxacin 24hrs,ranitidine 14hrs,amoxicillin 10hrs,paracetamol 14hrs,atenolol 36hrs,cephalexin 6hrs,ibuprofen 10hrs,diclofenac 14hrs,metformin 32hrs,omperazole 12hrs,metronidazole 48hrs,enalapril 8hrs,clarithromycin 24hrs,amlodipine 240hrs
|
Bioequivalence between marketed generic formulations and their corresponding innovator formulations and between 2 marketed generic formulations.
Bioequivalence will be assessed by the ratio of the area under the curve (AUC) (drug level vs time)and maximum levels (cmax) of two formulations and analyzed by the 90% confidence interval method.
The time is 3-5 plasma half-life of each drug.
|
ciprofloxacin 24hrs,ranitidine 14hrs,amoxicillin 10hrs,paracetamol 14hrs,atenolol 36hrs,cephalexin 6hrs,ibuprofen 10hrs,diclofenac 14hrs,metformin 32hrs,omperazole 12hrs,metronidazole 48hrs,enalapril 8hrs,clarithromycin 24hrs,amlodipine 240hrs
|
Intra-subject variation despite average bioequivalence
Time Frame: ciprofloxacin 24hrs,ranitidine 14hrs,amoxicillin 10hrs,paracetamol 14hrs,atenolol 36hrs,cephalexin 6hrs,ibuprofen 10hrs,diclofenac 14hrs,metformin 32hrs,omperazole 12hrs,metronidazole 48hrs,enalapril 8hrs,clarithromycin 24hrs,amlodipine 240hrs
|
Large intra-subject variation (a ratio of the test to reference formulation of AUC that is less than 80% or more than 120%) between innovator and generic formulation, despite showing average bioequivalence between the two formulations
|
ciprofloxacin 24hrs,ranitidine 14hrs,amoxicillin 10hrs,paracetamol 14hrs,atenolol 36hrs,cephalexin 6hrs,ibuprofen 10hrs,diclofenac 14hrs,metformin 32hrs,omperazole 12hrs,metronidazole 48hrs,enalapril 8hrs,clarithromycin 24hrs,amlodipine 240hrs
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- bioequivalence
- interchangeability
- innovator formulations
- generic formulations
- inter-patch variation
- quality of generic drug formulations on the market
- Interchangeability between marketed generic formulations
- prevalence of large intrasubject variability despite average bioequivalence
- Causes of large intrasubject variability
Other Study ID Numbers
- RAC 2101100
- project 10-BIO961-20 (Other Grant/Funding Number: Saudi National Comprehensive Plan for Science & Technology)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generic Drug Quality
-
Asan Medical CenterNational Clinical Research Coordination Center, Seoul, KoreaCompletedSevoflurane | General Anesthesia | Generic DrugsKorea, Republic of
-
Universidade Federal de Santa CatarinaCompletedGeneric Label | Brand-name Label
-
National Bureau of Economic Research, Inc.National Institute on Aging (NIA)CompletedConversion From Brand Name to Generic MedicationUnited States
-
Lille Catholic UniversityCompletedQuality of Life | Drug UseFrance
-
Inje UniversityCompletedQuality of Life | Drug Habit
-
Chulalongkorn UniversityMahidol UniversityCompleted
-
University of RochesterAgency for Healthcare Research and Quality (AHRQ)CompletedAdverse Drug Event, Potential Adverse Drug Event, and Quality MeasuresUnited States
-
Montreal Heart InstituteRoche Diagnostic Ltd.CompletedQuality of Life | Anticoagulants | Drug Monitoring | Pharmacy | Ambulatory CareCanada
-
Zhejiang UniversityCompletedQuality of Life | Complications | Adverse Drug Event | Length of Stay | Hospital CostsChina
-
University Hospital, GrenobleRecruitingDrug Resistant EpilepsyFrance
Clinical Trials on one of the 15 drugs listed below
-
GlaxoSmithKlineCompleted
-
Minamihanno HospitalCompleted
-
Yonsei UniversityCompletedDegenerative ArthritisKorea, Republic of
-
Colaris, Joost, M.D.UnknownChild | Treatment | Fracture | Forearm | MidshaftNetherlands
-
Hospital Clínico Universitario de ValladolidRecruitingBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Pain | Neurologic Manifestations | Headache Disorders | Headache Disorders, SecondarySpain
-
Shanghai Institute Of Biological ProductsCompleted
-
Centre Hospitalier Universitaire de NīmesCompletedTennis Elbow | Epicondylitis, Lateral HumeralFrance
-
Institut Claudius RegaudNovoCure Ltd.Not yet recruiting
-
Jiangsu Province Centers for Disease Control and...Completed
-
Université Catholique de LouvainRecruiting